Author

Judith Feucht

Memorial Sloan Kettering Cancer CenterORCID 0000-0002-8745-1079Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Approach:deep learning· 1

Frequent Co-Authors

Michel SadelainiD· 2 shared Achuth NairiD· 1 shared Alexander BirbrairiD· 1 shared Annalisa CabrioluiD· 1 shared Anthony F. DaniyaniD· 1 shared Brian D. BrowniD· 1 shared Caleb A. LareauiD· 1 shared Christopher Austin KlebanoffiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Michel SadelainORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologyNature CancerPeer-reviewedMay 22, 2026

Dendritic cells accelerate CAR T cells in irradiated tumors through chimeric synapses

Sammy Navarre, Maki Ishibashi, Achuth Nair…·Jalal Uddin Ahmed

This study shows dendritic cells enhance CAR T cell persistence in irradiated tumors by antigen-dressing and stimulating CAR T cells through chimeric receptors.

5 citationstop 1%

mouseCITE-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintSep 17, 2025

Repurposing passenger amplifications as Trojan horses identifies MPZL1 as a potent target for solid cancers

Sonia Jiménez Vázquez, Christos Patsis, Mara Mitstorfer…·Darjus Felix Tschaharganeh

The paper identifies MPZL1 as a therapeutic target in 1q-amplified solid cancers by repurposing passenger amplifications as Trojan horses for targeted therapy delivery.

DOI 10.1101/2025.09.17.675062

humanproteomics

𝕏 PostBluesky

ImmunologyNature CancerPeer-reviewedJul 22, 2025

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit

Fei Yi, Tal Cohen, Natalie Zimmerman…·Christopher Austin Klebanoff

This study identifies FASLG expression patterns and shows that FAS-L/FAS auto-regulation governs CAR-T and CAR-NK cell persistence, enhancing antitumor efficacy when FAS is inhibited.

55 citationstop 1%

humanscRNA-seq

𝕏 PostBluesky